Clinical guidelines and procedures for the use of methadone in the maintenance treatment of opioid dependence: abbreviated version

Abbreviated version of guidelines to aid medical practitioners in the selection and management of patients seeking methadone maintenance treatment for opioid dependence.

Page last updated: August 2003

Back to:

ISBN 0 642 82263 8
Publication approval number: 3265 (JN 7618)

Authors: Sue Henry-Edwards, Linda Gowing, Jason White, Robert Ali, James Bell, Rodger Brough, Nick Lintzeris, Alison Ritter, Allan Quigley.

Copyright statements
Introduction

Copyright statements

Paper-based publications

© Commonwealth of Australia 2003

This work is copyright. You may reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice an all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or by e-mail to copyright at copyright@health.gov.au.
Top of page

Internet sites

© Commonwealth of Australia 2003

This work is copyright. You may download, display, print and reproduce the whole or part of this work in unaltered form for your own personal use or, if you are part of an organisation, for internal use within your organisation, but only if you or your organisation do not use the reproduction for any commercial purpose and retain this copyright notice an all disclaimer notices as part of that reproduction. Apart from rights to use as permitted by the Copyright Act 1968 or allowed by this copyright notice, all other rights are reserved and you are not allowed to reproduce the whole or any part of this work in any way (electronic or otherwise) without first being given the specific written permission from the Commonwealth to do so. Requests and inquiries concerning reproduction and rights are to be sent to the Online, Services and External Relations Branch, Department of Health and Ageing, GPO Box 9848, Canberra ACT 2601, or by e-mail to copyright at copyright@health.gov.au.

Introduction

These guidelines have been prepared to aid medical practitioners in the selection and management of patients seeking treatment with methadone for opioid dependence.

These guidelines were prepared under the auspices of the National Expert Advisory Committee on Illicit Drugs (NEACID) in collaboration with the National Evaluation of Pharmacotherapies for Opioid Dependence (NEPOD) project, the Royal Australian College of General Practitioners (RACGP) and the Australian Professional Society on Alcohol and Other Drugs (APSAD), and are funded by the Australian Government Department of Health and Ageing.

These guidelines are based on national and international research literature and clinical experience with the use of methadone in Australia. These guidelines have undergone a rigorous process of review and have been formally endorsed by the RACGP and APSAD.

The contribution of various individuals and organisations in the drafting and review process is gratefully acknowledged.

The oral methadone preparations Methadone Syrup® and Biodone Forte® are registered only for treating heroin dependence in Australia. Methadone Syrup® contains 5 mg/ml methadone hydrochloride, sorbitol, glycerol, ethanol (4.75%), caramel, amber colouring and sodium benzoate while Biodone Forte® contains 5mg/ml methadone hydrochloride and permicol-red colouring.
Top of page